A patient with established RA on methotrexate (MTX) for 6 months has persistent moderate disease activity (DAS28 = 4.2). Per ACR guidelines, what is the next most appropriate step?

• A Add hydroxychloroquine to MTX (combination conventional DMARD therapy)
• B Substitute MTX with leflunomide
• C Switch to rituximab as second-line biologic
• D Add a TNF inhibitor (adalimumab, etanercept) to MTX ✓

Explanation

Per ACR 2021 RA guidelines, if moderate-to-high disease activity persists after adequate MTX therapy (typically 3–6 months at optimal dose), the next step is to add a biologic DMARD — preferably a TNF inhibitor (adalimumab, etanercept, certolizumab, golimumab, infliximab) due to the largest evidence base and long-term safety data. Addition of a JAK inhibitor (tofacitinib, baricitinib, upadacitinib) is an alternative. Rituximab is typically reserved for those who fail TNF inhibitors, have lymphoma or certain infections (where TNFi are contraindicated), or have positive rheumatoid factor/anti-CCP. Triple DMARD therapy (MTX + HCQ + sulfasalazine) is an alternative to biologics in resource-limited settings but generally inferior.

Reference: Harrison's Principles of Internal Medicine, 21st ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.